Skyrizi
E697097
Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Skyrizi canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7930812 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Skyrizi Context triple: [AbbVie, notableProduct, Skyrizi]
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
Prialt
Prialt is a non-opioid prescription pain medication (ziconotide) used for severe chronic pain, administered intrathecally and originally developed by Elan Pharmaceuticals.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Skyrizi Target entity description: Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
-
A.
Biktarvy
Biktarvy is a prescription combination antiretroviral medication used to treat HIV-1 infection in adults and certain children.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
-
D.
Prialt
Prialt is a non-opioid prescription pain medication (ziconotide) used for severe chronic pain, administered intrathecally and originally developed by Elan Pharmaceuticals.
-
E.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ prescription drug ⓘ |
| actsOn | immune system ⓘ |
| administrationFrequency |
every 12 weeks for maintenance in plaque psoriasis
ⓘ
every 12 weeks for maintenance in psoriatic arthritis ⓘ every 8 weeks for maintenance in Crohn’s disease (subcutaneous phase) ⓘ |
| approvalYear | 2019 ⓘ |
| approvedFor |
adult patients with active psoriatic arthritis
ⓘ
adult patients with moderate to severe plaque psoriasis ⓘ adult patients with moderately to severely active Crohn’s disease ⓘ |
| ATCCode | L04AC18 ⓘ |
| blackBoxWarning | risk of serious infections ⓘ |
| coDevelopedBy | Boehringer Ingelheim NERFINISHED ⓘ |
| commonAdverseEffect |
fatigue
ⓘ
headache ⓘ injection site reactions ⓘ upper respiratory tract infection ⓘ |
| contraindication | hypersensitivity to risankizumab ⓘ |
| developedBy | AbbVie NERFINISHED ⓘ |
| dosingForm |
on-body injector
ⓘ
prefilled pen ⓘ prefilled syringe ⓘ |
| hasGenericName | risankizumab NERFINISHED ⓘ |
| indication |
Crohn’s disease
ⓘ
moderate to severe plaque psoriasis ⓘ moderately to severely active Crohn’s disease ⓘ psoriatic arthritis ⓘ |
| initialDosing |
intravenous induction regimen for Crohn’s disease
ⓘ
subcutaneous loading doses for plaque psoriasis ⓘ |
| legalStatus | prescription only ⓘ |
| mechanismOfAction |
binds to IL-23 p19 subunit
ⓘ
selective inhibition of IL-23 pathway ⓘ |
| pharmacologicClass | humanized IgG1 monoclonal antibody ⓘ |
| pregnancyCategory | insufficient human data ⓘ |
| reduces |
inflammatory cytokine signaling mediated by IL-23
ⓘ
intestinal inflammation in Crohn’s disease ⓘ psoriasis skin lesions ⓘ signs and symptoms of psoriatic arthritis ⓘ |
| regulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| requiresMonitoring | signs and symptoms of infection ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targets |
IL-23 p19 subunit
NERFINISHED
ⓘ
interleukin-23 ⓘ |
| therapeuticClass |
IL-23 inhibitor
ⓘ
immunosuppressant ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Skyrizi Description of subject: Skyrizi is a prescription biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease by targeting the interleukin-23 (IL-23) pathway.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.